Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma

被引:5
|
作者
Lam, Selay [1 ]
Rizkalla, Kamilia [2 ]
Hsia, Cyrus C. [1 ]
机构
[1] London Hlth Sci Ctr, Dept Med, Div Haematol, London, ON, Canada
[2] London Hlth Sci Ctr, Dept Pathol, London, ON, Canada
来源
CASE REPORTS IN ONCOLOGY | 2011年 / 4卷 / 03期
关键词
Germ cell tumour; Choriocarcinoma; Hodgkin lymphoma; Mediastinal tumour;
D O I
10.1159/000334080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary mediastinal choriocarcinoma is a rare extragonadal germ cell malignancy. We describe the first case of a patient who developed mediastinal choriocarcinoma after treatment for Hodgkin lymphoma (HL). A 25-year-old man with classic HL, nodular sclerosis subtype, underwent treatment with splenectomy followed by radiation therapy. Unfortunately, his disease relapsed with a paraspinal mass, and he was subsequently treated with MOPP (mechlorethamine, Oncovin, procarbazine, and prednisone) alternating with ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine). He achieved a complete remission after 6 cycles. Ten years after treatment, the patient presented with a persistent cough, haemoptysis, right supraclavicular lymphadenopathy, and weight loss. His chest X-ray showed opacification of the lower right hemithorax with a widened mediastinum. Given unresponsiveness to several antibiotics and lack of evidence for lung volume loss, there were concerns over lung infiltration with relapsed lymphoma. Transbronchial fine needle aspiration biopsy suggested recurrence of his HL. MOPP alternating with ABVD was again given. Due to disease progression, brachytherapy as well as a cocktail of dexamethasone, cytarabine, and cisplatin were also tried. However, on a subsequent excisional lymph node biopsy, it turned out that the tumour was in fact choriocarcinoma and not relapsed HL. Unfortunately, despite aggressive therapy, the patient's disease rapidly progressed, and he died within 2 weeks.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 50 条
  • [41] Serum TARC and the diagnosis of relapsed Hodgkin lymphoma
    Farrell, K.
    Cannon, C.
    Tansey, P.
    Jackson, R.
    Jarrett, R. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 79 - 79
  • [42] Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
    Dinner, Shira
    Advani, Ranjana
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (08): : 968 - 976
  • [43] Lenalidomide In Patients with Relapsed or Refractory Hodgkin Lymphoma
    Boll, Boris
    Fuchs, Michael
    Reiners, Katrin S.
    Engert, Andreas
    Borchmann, Peter
    BLOOD, 2010, 116 (21) : 1166 - 1167
  • [44] CURRENT STRATEGIES IN REFRACTORY OR RELAPSED HODGKIN LYMPHOMA
    von Tresckow, B.
    Borchmann, P.
    Fuchs, M.
    Pluetschow, A.
    Engert, A.
    HAEMATOLOGICA, 2010, 95 : S31 - S31
  • [45] Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma
    Yun Choi
    Catherine S. Diefenbach
    Current Oncology Reports, 2020, 22
  • [46] Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma
    Choi, Yun
    Diefenbach, Catherine S.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (01)
  • [47] Nivolumab activity in relapsed Hodgkin's lymphoma
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (04): : E205 - E205
  • [48] Management of Relapsed and Refractory Hodgkin Lymphoma in 2018
    Rutherford, Sarah C.
    Leonard, John P.
    JAMA ONCOLOGY, 2018, 4 (08) : 1120 - 1121
  • [49] Pembrolizumab for relapsed or refractory Hodgkin lymphoma reply
    Kuruvilla, John
    LANCET ONCOLOGY, 2021, 22 (06): : E235 - E235
  • [50] A role for surgery in the treatment of relapsed Hodgkin lymphoma
    Fahy, A. S.
    Kong, I.
    Weitzman, S.
    Dix, D.
    Baruchel, S.
    Gerstle, J. T.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (01)